Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

40.18 +0.17 (+0.42%)
Official Closing Price Updated: 7:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Pfizer Invests $43 Billion to Battle Cancer
From Seagen Inc.
Via Business Wire
The 7 Most Undervalued Stocks to Buy in March 2023
These most undervalued stocks to buy are trading at hefty bargains offering tremendous upside potential ahead in the not-so-distant future 
Via InvestorPlace
7 Compelling Investment Opportunities for Beginning Investors in Their 30s
Even if you start out a bit late, it’s never too late, as these compelling investment opportunities for beginning investors prove. 
Via InvestorPlace
3 No-Brainer Dividend Stocks to Buy in March
Going with these great dividend stocks is an easy choice. 
Via The Motley Fool
Novavax Stock: Bear vs. Bull
The stock has brought investors eye-popping gains and losses over the past few years. 
Via The Motley Fool
Where Pfizer Stands With Analysts
 
Via Benzinga
Is Pfizer Stock a Buy Now?
Is this drug company just a "pandemic stock"? 
Via The Motley Fool
FDA Approves Pfizer's Fast Acting Migraine Drug Acquired Via $11B Biohaven Acquisition
 
Via Benzinga
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
From Pfizer Inc.
Via Business Wire
Pfizer Is Targeting an Acquisition That Could Be a Game Changer for Its Business
The company is rumored to be interested in buying Seagen. 
Via The Motley Fool
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
By Julian Richard, Benzinga 
Via TheNewswire.com
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome 
Via News Direct
7 Stocks at 52-Week Lows and Highly Attractive From Here
Although investors should generally avoid stocks at 52-week lows, for the speculator, these ideas may entice. 
Via InvestorPlace
Dividend Stocks Alert: 10 Top Holdings From the SCHD ETF
Dividend funds like the SCHD ETF are gaining traction ahead of its March 27 dividend payment. What are the top 10 holdings in the ETF? 
Via InvestorPlace
3 Must-Buy Income Champs as Fed Rates Head to 5%
There are plenty of high yield income stocks investors should consider buying, particularly as the Fed hikes interest rates to 5% and beyond. 
Via InvestorPlace
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
These companies aren't working on a vaccine, but a monoclonal antibody. 
Via Investor's Business Daily
BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Metabolism is the chemical process whereby the body produces energy from food. By breaking down carbohydrates and fats into sugars, the cells access fuel that can be used or stored via the liver or... 
Via Benzinga
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
FDA's Regulatory Delay is The Reason For Novavax, Lucira Health's Failure: WSJ Report
Failures of Covid vaccine maker Novavax Inc (NASDAQ: NVAX) and diagnostic start-up Lucira Health Inc (NASDAQ: LHDX) show that companies often succeed or fail, owing to the whims of the government.&nb 
Via Benzinga
The 7 Best Dividend Stocks to Buy in March 2023
These are some of the best dividend stocks to buy to help lower portfolio risk, while providing a steady income stream. 
Via InvestorPlace
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
 
Via Benzinga
US Stocks Could Consolidate As S&P 500, Nasdaq Futures Tick Up Ahead Of Fed Chair Powell's Congressional Testimony
Stocks could pause on Monday after returning to winning ways in the past week, as the focus shifts to Fed Chair Jerome Powell’s two-day Congressional testimony this week. Cues From Last Week’s... 
Via Benzinga
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks of 2023?
Can Lumen Technologies, Moderna, Baxter International, and Pfizer recover this year? 
Via The Motley Fool
Should You Give Up on Novavax?
After a spectacular 2020 performance, Novavax's shares have plummeted. 
Via The Motley Fool
How Much Did US Government Spend On mRNA Vaccine Technology Before And During The Pandemic? The Number Can Be Surprising
 
Via Benzinga
European Commission Keeps Mum On Talks Regarding Pfizer COVID-19 Vaccine Contract: Report
European Commission President Ursula von der Leyen remains silent on her dealings with Pfizer Inc (NYSE: PFE) regarding the EU's COVID-19 vaccine contract is hurting public trust. 
Via Benzinga
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK's Candidate Soon After Pfizer's
 
Via Benzinga
The 3 Best Recession Stocks to Buy for 2023
These are the best recession stocks for 2023 as they are low-beta stocks and represent companies with strong cash flows. 
Via InvestorPlace
Jim Cramer Says He's Known Novavax Is 'Worthless' For 'Very Long Time,' Trashes Company For Being Too 'Promotional'
Novavax Inc (NASDAQ: NVAX) shares are crashing Wednesday after the company warned that substantial doubt exists regarding its ability to continue.  Jim Cramer isn't surprised. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.